Record-Breaking Revenue Growth
Bavarian Nordic achieved close to DKK 4.8 billion in total revenues, marking a 32% increase compared to the previous year. This growth was driven by strong performance across both Travel Health and Public Preparedness segments.
Travel Health Business Expansion
The Travel Health business experienced its strongest quarter, with a 23% increase in sales year-over-year. Key products such as rabies and tick-borne encephalitis (TBE) vaccines showed significant market share gains, particularly in the U.S. and Germany.
Successful Launch of Chikungunya Vaccine
The chikungunya vaccine, Vimkunya, was launched in 10 countries and is expected to meet the target of DKK 75 million in sales during its first launch year. Future growth potential is projected as the market could grow to $500 million annually.
Public Preparedness Revenue Surge
The Public Preparedness segment secured DKK 3.1 billion in revenue, which is DKK 1 billion higher than the normal annual base, due to increased government contracts and initiatives.